ClinicalTrials.gov
public full text
Public Domain
Ph I/II of Vitamin D on Bone Mineral Density & Markers of Bone Resorption
Aromatase inhibitors are potent suppressors of breast cancer growth, but side effects include bone loss, fractures, arthralgias and myalgias. We hypothesize vitamin D administration might be beneficial in treating these symptoms and to protect bone.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Zoledronic Acid in Aromatase Inhibitor Induced Musculoskeletal Symptoms#1096184
- Evaluation of Oncoxin-Viusid® in Head and Neck Cancer#1126796
- Zoledronate in Preventing Osteoporosis in Patients With Primary Malignant Glioma#902433
- Antineoplaston Therapy in Treating Women With Stage IV Breast Cancer#1198546
- Antineoplaston Therapy in Treating Patients With Stage III or Stage IV Ovarian Cancer#1032966
Record · ID 1383318
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive